Growth Metrics

Jazz Pharmaceuticals (JAZZ) Non-Current Debt (2016 - 2025)

Jazz Pharmaceuticals has reported Non-Current Debt over the past 15 years, most recently at $4.3 billion for Q4 2025.

  • Quarterly Non-Current Debt fell 28.78% to $4.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.3 billion through Dec 2025, down 28.78% year-over-year, with the annual reading at $4.3 billion for FY2025, 28.78% down from the prior year.
  • Non-Current Debt was $4.3 billion for Q4 2025 at Jazz Pharmaceuticals, roughly flat from $4.3 billion in the prior quarter.
  • Over five years, Non-Current Debt peaked at $6.5 billion in Q2 2021 and troughed at $1.9 billion in Q1 2021.
  • The 5-year median for Non-Current Debt is $5.7 billion (2023), against an average of $5.3 billion.
  • Biggest five-year swings in Non-Current Debt: surged 238.85% in 2021 and later fell 28.78% in 2025.
  • Tracing JAZZ's Non-Current Debt over 5 years: stood at $6.0 billion in 2021, then decreased by 5.41% to $5.7 billion in 2022, then fell by 10.28% to $5.1 billion in 2023, then increased by 18.98% to $6.1 billion in 2024, then fell by 28.78% to $4.3 billion in 2025.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $4.3 billion, $4.3 billion, and $4.3 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.